Home » Stocks » Gene Biotherapeutics

Gene Biotherapeutics Inc. (CRXM)

Stock Price: $0.0788 USD 0.0101 (14.70%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 1.13M
Revenue (ttm) n/a
Net Income (ttm) -3.07M
Shares Out 14.37M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.0788
Previous Close $0.0687
Change ($) 0.0101
Change (%) 14.70%
Day's Open 0.0690
Day's Range 0.0680 - 0.0788
Day's Volume 236,570
52-Week Range 0.0204 - 0.1900

More Stats

Market Cap 1.13M
Enterprise Value 956,304
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 14.37M
Float 12.78M
EPS (basic) -0.3
EPS (diluted) -0.29
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 150,251
Short Ratio 1.03
Short % of Float 2.47%
Beta 1.66
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.36
Revenue n/a
Operating Income -3.07M
Net Income -3.07M
Free Cash Flow -2.55M
Net Cash 176,367
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -758.60%
ROE n/a
ROIC 68.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$2.00*
Low
2.00
Current: $0.0788
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2016201520142013201220112010200920082007
Revenue---0.110.06-0.240.440.420.45
Revenue Growth---83.81%---45.05%6.72%-6.51%-
Gross Profit---0.040.01-0.240.440.420.45
Operating Income-2.84-3.11-3.58-6.91-8.29-7.42-6.77-8.71-17.15-17.44
Net Income-2.92-3.70-5.51-8.91-8.32-7.13-4.74-11.68-24.60-25.32
Shares Outstanding13.3312.8611.127.005.924.253.692.452.251.97
Earnings Per Share-0.28-0.34-0.50-1.33-1.41-1.60-1.20-4.80-11.00-12.80
Operating Cash Flow-2.02-1.05-2.62-6.03-9.21-7.67-7.41-11.61-16.61-21.36
Capital Expenditures-0.17---0.02-0.02--0.05--0.68-1.23
Free Cash Flow-2.20-1.05-2.62-6.05-9.23-7.68-7.47-11.61-17.30-22.58
Cash & Equivalents0.930.020.220.022.334.928.074.791.508.32
Total Debt--------4.044.72
Net Cash / Debt0.930.020.220.022.334.928.074.79-2.533.59
Assets1.110.040.752.797.817.509.515.4810.3016.93
Liabilities4.403.832.431.601.441.422.087.6311.058.50
Book Value-3.14--1.681.196.376.087.43-2.15-0.758.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gene Biotherapeutics Inc.
Country United States
Employees 6
CEO Christopher J. Reinhard

Stock Information

Ticker Symbol CRXM
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: CRXM

Description

Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.